TY - JOUR
T1 - Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma
AU - Geraldes, Catarina
AU - Roque, Adriana
AU - Sarmento-Ribeiro, Ana Bela
AU - Neves, Manuel
AU - Ionita, Alina
AU - Gerivaz, Rita
AU - Tomé, Ana
AU - Afonso, Sofia
AU - Silveira, Maria Pedro
AU - Sousa, Patrícia
AU - Bergantim, Rui
AU - João, Cristina
PY - 2024/3
Y1 - 2024/3
N2 - Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to novel agents, sometimes in combination with conventional therapies, makes this management even more challenging. A careful balance between treatment efficacy and its tolerability should be considered for every patient. During treatment, a close monitoring of comorbidities, disease-related manifestations and treatment side effects is recommended, as well as a proactive approach, with reinforcement of information and patient awareness for the early recognition of adverse events, allowing prompt therapeutic adjustments. In this review, we discuss various issues that must be considered in the treatment of MM patients, while giving practical guidance for monitoring, prevention and management of myeloma-related manifestations and treatment-related toxicities.
AB - Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to novel agents, sometimes in combination with conventional therapies, makes this management even more challenging. A careful balance between treatment efficacy and its tolerability should be considered for every patient. During treatment, a close monitoring of comorbidities, disease-related manifestations and treatment side effects is recommended, as well as a proactive approach, with reinforcement of information and patient awareness for the early recognition of adverse events, allowing prompt therapeutic adjustments. In this review, we discuss various issues that must be considered in the treatment of MM patients, while giving practical guidance for monitoring, prevention and management of myeloma-related manifestations and treatment-related toxicities.
KW - anticancer drug toxicities
KW - cancer management
KW - delivery of health care
KW - multiple myeloma
KW - myeloma-related manifestations
KW - real life practical considerations
UR - http://www.scopus.com/inward/record.url?scp=85189641261&partnerID=8YFLogxK
U2 - 10.3389/fonc.2024.1282300
DO - 10.3389/fonc.2024.1282300
M3 - Review article
AN - SCOPUS:85189641261
SN - 2234-943X
VL - 14
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1282300
ER -